Previous 10 | Next 10 |
Keros Therapeutics (NASDAQ:KROS): Q3 GAAP EPS of -$0.87 misses by $0.15. Cash and cash equivalents of $221.35M. Press Release For further details see: Keros Therapeutics EPS misses by $0.15
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...
LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...
While the S&P 500 index dropped ~2.2% over the week, its healthcare constituents fell ~3.5%, posting the fourth consecutive weekly loss, as the sector — dragged down by life sciences and services — became the worst performer. Headlining the week was Merck (NYSE:MRK) wit...
Gainers: Sonoma Pharmaceuticals (NASDAQ:SNOA) +33%, Evelo Biosciences (NASDAQ:EVLO) +12%, ZIVO Bioscience (NASDAQ:ZIVO) +12%, Viridian Therapeutics (NASDAQ:VRDN) +7%, Harpoon Therapeutics (NASDAQ:HARP) +7%. Losers: Altimmune (NASDAQ:ALT) -20%, ...
Gainers: Red Cat (OTCQB:RCAT) +46%. AerSale (NASDAQ:ASLEW) +38%. Keros (NASDAQ:KROS) +28%. Camber Energy (NYSE:CEI) +27%. Puhui Wealth Investment Management (NASDAQ:PHCF) +27%. ENGlobal (NASDAQ:ENG) +25%. Paltalk (NASDAQ:PALT) +25%. Aemetis (NASDAQ:AMTX) +20%. Southwestern (NYSE:SWN) +19%. Ne...
Gainers: Cellect Biotechnology (NASDAQ:APOP) +24%, Keros Therapeutics (NASDAQ:KROS) +24%, Gossamer Bio (NASDAQ:GOSS) +17%, Seelos Therapeutics (NASDAQ:SEEL) +16%, DiaMedica Therapeutics (NASDAQ:DMAC) +9%. Losers: ASLAN Pharmaceuticals (NASDAQ:ASLN)...
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musc...
LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
News, Short Squeeze, Breakout and More Instantly...
Keros Therapeutics Inc. Company Name:
KROS Stock Symbol:
NASDAQ Market:
Keros Therapeutics Inc. Website:
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...